1. Glucagon-like peptide-1 agonist use for obesity treatment in patients with left ventricular assist devices
- Author
-
Michele Edwards, MSN, APRN, Melanie Thomas, MSN, APRN, Maryjane Farr, MD, MSc, Densey Varghese, MSN, APRN, Lauren K. Truby, MD, MS, Jennifer T. Thibodeau, MD, MSCS, Mark H. Drazner, MD, MSc, Matthias Peltz, MD, Justin L. Grodin, MD, MPH, and Nicholas S. Hendren, MD
- Subjects
LVAD ,obesity ,GLP-1a ,heart failure ,heart transplant ,Surgery ,RD1-811 ,Specialties of internal medicine ,RC581-951 - Abstract
Glucagon-like peptide-1 agonists are effective weight loss treatments, yet few data are available regarding their use in patients with durable left ventricular assist devices. We report our single-center experience with glucagon-like peptide-1 agonist use in 21 patients with World Health Organization class I to III obesity on durable left ventricular assist device support. During therapy, patients experienced a median weight change of −12.4 (−20.0 to −2.9) kg and a −7.4% (−16.3 to −2.1) change in body weight with a median time on glucagon-like peptide-1 agonist therapy of 12 (6-22) months. Of these, 17 of 21 patients lost weight (median change −14.0kg [−21.8 to −5.3], −9.5% [−18.0 to −4.0] body weight) and 9 of 21 had a speed reduction. No major adverse events were attributed to glucagon-like peptide-1 agonist therapy. At our center, glucagon-like peptide-1 agonists use was well tolerated, safe, and associated with weight loss in patients with durable left ventricular assist devices.
- Published
- 2024
- Full Text
- View/download PDF